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Abstract
Aims/hypothesis Obesity is associated with a state of chronic
low-grade inflammation that is believed to contribute to the
development of skeletal muscle insulin resistance. However,
the extent to which local and systemic elevation of cytokines,
such as monocyte chemoattractant protein 1 (MCP-1), inter-
feres with the action of insulin and promotes insulin resistance
and glucose intolerance in muscle remains unclear. Here, we
aim to investigate the effect of muscle-specific overexpression
of MCP-1 on insulin sensitivity and glucose tolerance in lean
and obese mice.
Methods We used Mck–Mcp-1 transgenic (Tg) mice
characterised by muscle-specific overexpression of Mcp-1
(also known as Ccl2) and elevated plasma MCP-1 levels.
Mice were fed either chow or high-fat diet for 10 weeks.
Numerous metabolic variables were measured, including glu-
cose and insulin tolerance tests, muscle insulin signalling and
plasma NEFA, triacylglycerol, cholesterol, glucose and insulin.
Results Despite clearly promoting skeletal muscle inflamma-
tion, muscle-specific overexpression of Mcp-1 did not
influence glucose tolerance or insulin sensitivity in either lean
chow-fed or diet-induced obese mice. In addition, plasma
NEFA, triacylglycerol, cholesterol, glucose and insulin were
not affected by MCP-1 overexpression. Finally, in vivo
insulin-induced Akt phosphorylation in skeletal muscle
did not differ between Mcp-1-Tg and wild-type mice.
Conclusions/interpretation We show that increased MCP-
1 production in skeletal muscle and concomitant elevat-
ed MCP-1 levels in plasma promote inflammation in
skeletal muscle but do not influence insulin signalling
and have no effect on insulin resistance and glucose
tolerance in lean and obese mice. Overall, our data ar-
gue against MCP-1 promoting insulin resistance in skel-
etal muscle and raise questions about the impact of in-
flammation on insulin sensitivity in muscle.
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Over recent decades, the global prevalence of obesity has been
increasing steadily, concurrent with major changes in diet and
lifestyle. Obesity is often accompanied by a number of meta-
bolic perturbations, including insulin resistance, hyper-
insulinaemia, dyslipidaemia and hypertension, which together
substantially increase the risk for type 2 diabetes and cardio-
vascular disease [1–4]. Development of insulin resistance is
generally considered as an early event that drives many of the
metabolic disturbances associated with obesity. Since insulin
resistance was first recognised several decades ago, a number
of ideas have been put forward to try and explain the link
between excess adiposity and reduced tissue sensitivity to
insulin. Currently, major emphasis is placed on the detrimental
effect of fat stored outside the adipose compartment.
Additionally and alternatively, inflammation is increasingly
believed to play a pivotal role in the development of insulin
resistance and type 2 diabetes (reviewed in [5]). According to
this so-called inflammatory hypothesis, obesity is cha-
racterised by expansion of the adipose depot, giving rise to
adipocyte hypertrophy, hypoxia and endoplasmic reticulum
(ER) stress, which in turn causes enhanced production of
cytokines and chemokines [6–8]. Cytokines such as TNFα,
IL-1β, IL-6, IL-8 and monocyte chemoattractant protein 1
(MCP-1) promote the attraction of different immune cells in
obese adipose tissue, including proinflammatory macro-
phages and B cells, whereas regulatory T cells, natural killer
T cells and eosinophils become less abundant [9]. These im-
mune cells are producers of a host of different cytokines/
chemokines and together with the hypertrophic adipocytes
contribute to a state of chronic low-grade inflammation.
In vitro studies abound indicating that proinflammatory cyto-
kines are able to inhibit insulin signalling and thus promote
the development of insulin resistance in fat cells and muscle
cells. For example, Eckel and colleagues found that the che-
mokine MCP-1 impaired insulin signalling and reduced
insulin-stimulated glucose uptake in muscle cells, suggesting
that MCP-1 may represent a molecular link in the negative
crosstalk between adipose tissue and skeletal muscle [10].
What is less clear is whether the obesity-induced adipose tis-
sue inflammation leads to the increments in cytokine levels in
blood plasma necessary to interfere with the action of insulin
and to cause insulin resistance in muscle in vivo. This is par-
ticularly relevant since it has been calculated that approxi-
mately 80% of insulin-induced glucose disposal is accounted
for by skeletal muscle glucose uptake. Studies performed
using mice characterised by fat-specific overexpression of
Mcp-1 (also known as Ccl2) or expression of a dominant-
negative mutant of Mcp-1 suggest that fat-derived MCP-1
reduces glucose tolerance and insulin sensitivity and blunts
insulin-mediated signalling [11, 12]. However, the full scope
of the role of adipose tissue inflammation and the impact of
specific cytokines such as MCP-1 on whole-body glucose
tolerance and insulin’s action in skeletal muscle remains
ambiguous.
Importantly, recent studies indicate that elevated MCP-1
expression not only occurs during obesity but is also a feature
of physical exercise. Specifically, levels of MCP-1 mRNA in
skeletal muscle and levels of MCP-1 protein in plasma were
found to be increased upon acute exercise, leading to the clas-
sification of MCP-1 as myokine or exercise factor [13–17]. In
skeletal muscle, MCP-1 is known to promote macrophage
infiltration after (severe) tissue damage [18, 19]. In contrast,
chronic exercise results in a decrease in MCP-1 plasma levels
[20, 21]. The features of MCP-1 are reminiscent of IL-6.
Production of IL-6 in adipose tissue has been shown to be
increased during obesity and contributes to obesity-
associated low-grade inflammation (reviewed in [22]). At
the same time, production of IL-6 in skeletal muscle and plas-
ma IL-6 levels are increased in response to acute exercise and
have been suggested to potentially confer a positive effect on
insulin signalling and insulin sensitivity in skeletal muscle
[23], although recent data argue against that notion [24].
How inflammatory mediators may have a beneficial role in
the context of physical exercise yet promote insulin resistance
during obesity represents somewhat of a conundrum.
The aim of the present study was to assess the extent to
which elevation of MCP-1 production in muscle and elevated
MCP-1 levels in plasma may be able to interfere with insulin
signalling in skeletal muscle and promote insulin resistance.
To this end, we took advantage ofMck–Mcp-1 transgenic (Tg)
mice, which specifically overexpress Mcp-1 in skeletal mus-
cle. Our studies indicate that elevation of MCP-1 production
in skeletal muscle and elevated MCP-1 levels in plasma pro-
mote inflammation in skeletal muscle but do not influence
insulin signalling in skeletal muscle and have no effect on
insulin resistance and glucose tolerance in lean and obese
mice.
Methods
Animals Animal studies were carried out using wild-type
(WT) andMck–Mcp-1 Tgmice, all on a C57Bl/6J background
[25]. The mice were kindly donated by D. Patsouris
(Université Claude Bernard Lyon 1, France). Only male mice
were used. Mice were kept in temperature controlled rooms
(21±1°C) on a 12 h light–dark cycle. For the studies using
chow-fed mice, 16 WT and 19 Mcp-1-Tg mice were fed reg-
ular chow (RMH-B Arie Blok, Woerden, the Netherlands). At
14–17 weeks of age, eight mice per group were subjected to
an intraperitoneal glucose tolerance test and a week later to an
intraperitoneal insulin tolerance test. Mice were euthanised at
17–20 weeks of age after a 6 h fast at zeitgeber time
(ZT)7–ZT9. Before being euthanised, eight mice of each
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genotype received an intraperitoneal injection of insulin
(2 U/kg body weight in 100 μl saline [154 mmol/l NaCl],
n=4 per genotype) or saline (100 μl, n=4 per genotype)
followed by euthanasia exactly 5 min later by cervical
dislocation. For the remaining mice, blood was collected by
orbital puncture under isoflurane anaesthesia and mice were
euthanised by cervical dislocation. For the high-fat feeding
study, 12 WT and 12 Mcp-1-Tg mice were fed regular chow
(RMH-B Arie Blok) after weaning. At 12–16 weeks of age,
mice were switched to a high-fat diet (HFD) containing 60
energy% fat (D12492; Research Diets Inc., New Brunswick,
NJ, USA). Food intake and body weights were registered
weekly. After 8 weeks of high-fat feeding, mice were subject-
ed to an intraperitoneal glucose tolerance test and a week later
to an intraperitoneal insulin tolerance test. Mice were
euthanised after 10 weeks of high-fat feeding after a 6 h fast
at ZT7–ZT9. Before being euthanised, four mice of each ge-
notype received an intraperitoneal injection of insulin (2 U/kg
body weight in 100 μl saline, n=2 per genotype) or saline
(100 μl, n=2 per genotype) followed by euthanasia exactly
5 min later by cervical dislocation. For the remainder of the
mice, blood was collected by orbital puncture under isoflurane
anaesthesia and mice were euthanised by cervical dislocation.
Tissues were excised and immediately frozen in liquid nitro-
gen followed by storage at −80°C. All experiments were blind
to group and outcome assessment. All animal experiments
were authorised by the animal welfare committee of
Wageningen University.
Intraperitoneal glucose tolerance test After a 6 h fast mice
were injected intraperitoneally with glucose (1.2 g/kg body
weight for mice on chow, 0.8 g/kg body weight for mice on
HFD). Blood was collected by tail bleeding after 0, 15, 30, 60,
90 and 120 min, and glucose was measured using an Accu-
Chek compact (Roche Diagnostics, Almere, the Netherlands).
Intraperitoneal insulin tolerance test After a 6 h fast mice
were injected intraperitoneally with insulin (0.75 U/kg body
weight). Blood was collected by tail bleeding after 0, 15, 30,
45, 60 and 90 min, and glucose was measured using an Accu-
Chek compact (Roche Diagnostics).
Histological stainings Histological analysis of musculus gas-
trocnemiusmorphology andmacrophage infiltrationwas done
using hematoxylin and eosin (H&E) staining. On the day of
euthanasia, samples were frozen in isopentane mixed with dry
ice and stored at −80°C. Tissue was embedded in Tissue-Tek
O.C.T. Compound (Sakura Finetek, Alpen aan de Rijn, the
Netherlands), sectioned at 10 μm in a cryostat chamber, fixed
on a Superfrost glassslide, left to dry for 30 min and stored at
−20°C. Samples were stained at room temperature in Mayer
hematoxylin solution for 10 min and in eosin Y solution for
30 s.
Measurement of plasma variables Blood was collected into
EDTA-coated tubes. Blood samples were placed on ice and
centrifuged at 4°C for 10 min at 10,000g. Plasma was collect-
ed and stored at −80°C. To measure plasma MCP-1 concen-
tration a DuoSet ELISA Development kit against mouse
MCP-1 was used (R&D Systems, Minneapolis, MN, USA).
For insulin measurements an ultra-sensitive mouse insulin
ELISA kit was used (Crystal chemicals, Downers Grove, IL,
USA). For the other plasma measurements the following kits
were used: NEFA Reagent set, Triglycerides Liquicolor,
Cholesterol Liquicolor (all Instruchemie, Delfzijl, the
Netherlands) and Glucose GOD FS (DiaSys, Holzheim,
Germany). All measurements were performed according to
the manufacturers’ protocols.
Affymetrix microarray Microarray analysis was performed
on RNA of the musculus gastrocnemius as described in the
electronic supplementary material (ESM) Methods.
RNA isolation and quantitative real-time PCR Total RNA
was extracted from different mouse tissues using TRIzol re-
agent (Invitrogen, Bleiswijk, the Netherlands) and a
Tissuelyser II (Qiagen, Venlo, the Netherlands). Reverse tran-
scription was performed using Superscript II and oligo(dT)
primers (Invitrogen). PCR-amplifications were carried out
using iQ SYBR Green Supermix on a CFX384 Touch real-
time PCR detection system (Bio-Rad, Hercules, CA, USA).
The sequences of the primers used for quantitative real-
time PCR (qPCR) are shown in ESM Table 1. All genes were
normalised to 36b4. Primer efficiencies were determined
using LinRegPCR v11.1 (http://LinRegPCR.nl) [26].
Relative expression of the transcript levels was calculated as
described previously [27].
Western blotting Total protein extracts were obtained from
musculus gastrocnemius to detect MCP-1. Tissue was
homogenised using a Tissuelyser II (Qiagen) in protein extrac-
tion buffer without bromophenol blue (62.5 mmol/l Tris HCl,
pH 6.8, 2% SDS, 10% glycerol and 10 mmol/l dithiothreitol)
and protein concentration was measured using Bradford pro-
tein assay. Protein (50 μg) was boiled, subjected to SDS-
PAGE and proteins transferred to nitrocellulose membrane
(Immobilon; Millipore, Billerica, MA, USA). Membranes
were blocked and incubated with anti-MCP-1 (R17; Santa
Cruz, Dallas, TX, USA) and anti-Actin (Sigma Aldrich,
St Louis, MO, USA).
To obtain total protein extracts from musculus gastrocne-
mius to detect phospho-Akt, tissue was homogenised using a
Tissuelyser II (Qiagen) in protein extraction buffer with phos-
phatase inhibitors (50 mmol/l Tris HCl, pH 4.7, 1 mmol/l
EDTA, 150 mmol/l NaCl, 1% NP40, 0.25% sodium
deoxycholate, 2 mmol/l sodium orthovanadate and 5 mmol/l
sodium fluoride, containing freshly added protease inhibitor
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cocktail [Roche Applied Science, Penzberg, Germany]). After
being centrifuged at 20,800g for 10 min at 4°C, supernatant
fractions were collected and 50 μg of protein was boiled with
Laemmli sample buffer. The protein was subjected to SDS-
PAGE and transferred to a polyvinylidene difluoride mem-
brane (Immobilon; Millipore). Membranes were blocked and
incubated with anti-Akt (in house), anti-phospho-Akt
(Ser473) (Cell Signaling Technology, Danvers, MA, USA)
and anti-Actin (Sigma Aldrich). Quantification was carried
out using ImageJ 1.49m (http://imagej.nih.gov).
Statistical analysis For statistical analysis Student’s t test was
used. Data are means±SEM and p<0.05 is considered statis-
tically significant. One mouse from the WT group, fed HFD,
was excluded from subsequent analysis because it was mis-
takenly injected with a higher dose of insulin during the insu-
lin tolerance test. Some qPCR data on gene expression were
excluded from the results section because the genes were
expressed at a low level, with Ct values greater than 32 in both
the WT and Mcp-1-Tg mice.
Results
Skeletal muscle-specific overexpression of MCP-1 results
in a local inflammatory response To assess the impact of
muscle-specific overexpression of MCP-1 on whole-body
glucose homeostasis and insulin sensitivity, we used Tg mice
that overexpressMcp-1 under the control of theMck promotor
[25]. The marked overexpression of Mcp-1 in the transgenic
mice was confirmed at the mRNA level in the musculus gas-
trocnemius, vastus and soleus, whereasMcp-1was only weak-
ly induced or not induced in the liver and white adipose tissue
(WAT), respectively (Fig. 1a). Since the overexpression of
Mcp-1 was most pronounced in the gastrocnemius muscle,
we used the gastrocnemius in all follow-up experiments.
Overexpression of Mcp-1 in the gastrocnemius of the Mcp-1-
Tg mice was confirmed at the protein level (Fig. 1b).
Furthermore, the plasma concentration of MCP-1 in the Mcp-
1-Tg mice was increased approximately 4.4-fold compared
with WTmice, indicating that MCP-1 is secreted from skeletal
muscle (Fig. 1c). H&E staining indicated enhanced inflamma-
tion in the gastrocnemius of the Mcp-1-Tg mice as compared
with WT mice, as illustrated by infiltration of macrophages
between the muscle fibres (Fig. 1d). In addition, mRNA levels
of Il1b and the macrophage markers F4/80 and Cd68 were
significantly increased in the gastrocnemius of the Mcp-1-Tg
mice (Fig. 1e). In contrast, expression of the same inflamma-
tory markers in liver (Fig. 1f) andWAT (Fig. 1g) did not reveal
any differences between WT and Mcp-1-Tg mice.
Next, we performed microarray analysis on the gastrocne-
mius of eight WT mice and eightMcp-1-Tg mice to study the
overall effect of MCP-1 overexpression on gene expression in
skeletal muscle. Overexpression of MCP-1 caused a clear in-
flammatory gene expression signature (Fig. 2a). The 25 most
highly induced genes were all involved in inflammation and/
or immunity, including the genes encoding lysozyme (Lyz1),
the immune cells surface markers Cd52 and Cd180, and the
secreted protein Retnla. Interestingly, the most highly induced
gene was Mcp-1 (99-fold), followed by its receptor Ccr2.
Gene set enrichment analysis (GSEA) corroborated the pro-
nounced induction of inflammation and immune-related path-
ways. Specifically, the top 20 of most highly enriched path-
ways are all linked to inflammation, including chemokine
signalling, Tcell receptor signalling, phagocytosis and inflam-
matory disease-related pathways (Fig. 2b). The complete list
of significantly regulated genes (q value<0.05) is presented in
ESM Table 2. Taken together, these data indicate that MCP-1
overexpression promotes inflammation in skeletal muscle.
No metabolic phenotype can be observed in mice
overexpressing MCP-1 in skeletal muscle when fed a
normal chow diet To test whether skeletal muscle-specific
overexpression of MCP-1 and associated inflammation may
also influence glucose homeostasis and insulin sensitivity,
Mcp-1-Tg mice and their WT littermates were subjected to
detailed metabolic characterisation. Mcp-1-Tg and WT mice
had similar weights of musculus gastrocnemius, musculus
vastus, liver and WAT (Fig. 3a). Intriguingly, the results of
an intraperitoneal insulin tolerance test (Fig. 3b) and intraper-
itoneal glucose tolerance test (Fig. 3c) did not differ between
Mcp-1-Tg andWTmice. In addition, we analysed the effect of
muscle-specific MCP-1 overexpression on the sensitivity of
muscle to i.p. injection of insulin, using phosphorylation of
Akt as a readout. Insulin injection markedly stimulated Akt
phosphorylation in the gastrocnemius muscle (Fig. 3d).
However, no significant difference in phospho-Akt could be
observed between WT and Mcp-1-Tg mice, indicating that
MCP-1 overexpression does not alter insulin-dependent sig-
nalling in skeletal muscle. Finally, theMcp-1-Tg mice did not
show any changes in plasma concentrations of NEFA, triacyl-
glycerol, cholesterol, glucose or insulin when compared with
WT mice (Fig. 3e–i). Taken together, our results indicate a
lack of an effect of muscle-specific MCP-1 overexpression
on insulin sensitivity and glucose homeostasis in mice fed a
normal chow diet.
HFD feeding does not result in metabolic alterations in
muscle-specific Mcp-1-Tg mice One possible explanation
for the lack of effect of MCP-1 overexpression on variables
associated with insulin sensitivity is related to the fact that the
mice were fed normal chow and were therefore lean. To de-
termine the impact of muscle-specific overexpression of
MCP-1 on glucose homeostasis and insulin sensitivity in the
context of obesity and insulin resistance, muscle-specific
Mcp-1-Tg and WT littermates were rendered obese and
Diabetologia (2016) 59:624–633 627
insulin resistant by chronic high-fat feeding. The muscle-
specific overexpression of Mcp-1 in the Mcp-1-Tg mice was
maintained after HFD (Fig. 4a), accompanied by a 10.9-fold
increase in plasma MCP-1 levels (Fig. 4b). H&E staining
showed more pronounced macrophage infiltration in the gas-
trocnemius of the Mcp-1-Tg mice compared with WT mice
(Fig. 4c). In addition, mRNA levels of IL1b and the macro-
phage markers F4/80 and Cd68 were significantly increased
in the gastrocnemius of the Mcp-1-Tg mice (Fig. 4d). In con-
trast, expression of inflammatory markers remained un-
changed in liver and adipose tissue of the Mcp-1-Tg mice,
with the exception of macrophage marker F4/80 and
alternatively-activated macrophage marker Cd206, which
were both significantly reduced in liver of Mcp-1-Tg mice
(ESM Fig. 1). Whole-body weight (Fig. 4e) and food intake
(Fig. 4f) did not differ betweenMcp-1-Tg mice and WT mice
on HFD, and there was no difference in weights of the
musculus gastrocnemius, musculus vastus, liver and WAT
(Fig. 4g). An intraperitoneal insulin tolerance test and glucose
tolerance test revealed decreased glucose tolerance in mice fed
HFD compared with chow. However, no differences in insulin
and glucose tolerance were detected when comparing diet-
induced obese Mcp-1-Tg mice with WT mice (Fig. 5a, b). As
observed in chow-fed mice, insulin-induced Akt phosphoryla-
tion was similar in the gastrocnemius of HFD-fed Mcp-1-Tg
mice compared with HFD-fed WT mice (Fig. 5c). In addition,
none of the plasma metabolites measured was significantly
changed in the Mcp-1-Tg mice compared with WT mice.
(Fig. 5d–h). Finally, hepatic expression of insulin-sensitive
genes Gk, Srebp1c (also known as Srebf1), Acc1 (Acaca), and
Pepck (Pck1) was unaffected by muscle-specific MCP-1 over-
expression (Fig. 5i). Taken together, muscle-specific overex-
pression ofMCP-1 did not affect insulin sensitivity and glucose
homeostasis in obese insulin-resistant mice.
Discussion
The aim of the present study was to assess to what extent
elevation of MCP-1 production in muscle and elevated
MCP-1 levels in plasma interfere with insulin signalling in



















































































































































Fig. 1 Skeletal muscle-specific overexpression of MCP-1 provokes in-
flammation. (a) Relative gene expression of Mcp-1 measured by qPCR;
n=8 (WT mice) or n=11 (Mcp-1-Tg mice). (b) Representative western
blot analysis of MCP-1 overexpression in Mcp-1-Tg mice. (c) Plasma
concentration of MCP-1; n=8 (WT mice) or n=11 (Mcp-1-Tg mice).
(d) H&E staining of representative sections of musculus gastrocnemius
of WT and Mcp-1-Tg mice (magnification×200). Arrowheads indicate
macrophage infiltration. Insert: H&E staining of musculus vastus (mag-
nification ×1,000), showing immune cell infiltrate. e–g: Relative gene
expression of Il6, Il1b, F4/80 and Cd68 in gastrocnemius (e), liver (f)
and WAT (g) measured by qPCR; n=8 (WT mice) or n=11 (Mcp-1-Tg
mice). White bars, WTmice; black bars,Mcp-1-Tg mice. Data are means
±SEM; *p<0.05 and ***p<0.001 according to Student’s t test for WT vs
Mcp-1-Tg mice
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an Mck-Mcp-1-Tg mouse model that specif ical ly
overexpresses MCP-1 in skeletal muscle was used. We show
that muscle-specific overexpression of MCP-1 promotes in-
flammation in skeletal muscle but does not influence insulin
signalling in skeletal muscle and has no effect on whole-body
insulin sensitivity and glucose tolerance in either lean or obese
mice. These findings therefore indicate that muscle inflamma-
tion by itself is not sufficient to evoke whole-body insulin
resistance.
Studies to date have not been consistent in establishing a
causal relation between muscle-specific stimulation or repres-
sion of inflammatory molecules and alterations in insulin sen-
sitivity. On the one hand, it has been shown that over-
production of constitutively activated c-Jun N-terminal kinase
in skeletal muscle impairs insulin signalling in mice by
modulating serine and threonine phosphorylation of Akt and
IRS-1 [28]. On the other hand, muscle-specific ablation of IκB
kinase 2, resulting in reduced activation of the transcription
factor nuclear factor-κB (NF-κB), had no effect on obesity-
induced insulin resistance and on insulin signalling in muscle
[29]. Similarly, muscle-specific ablation of signal transducer
and activator of transcription 3 (STAT3), another transcription
factor activated by proinflammatory cytokines, showed no
effect on obesity-induced insulin resistance, as assessed by
glucose tolerance test, clamp studies and measurement of
2-deoxyglucose uptake [30]. Our study indicates that local
activation of inflammation in muscle via MCP-1 overexpres-
sion does not affect insulin sensitivity and insulin action.
Along the same lines, overexpression of NF-κB subunit p65
and IκBKβ in single muscles of rats using in vivo
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Fig. 2 MCP-1 overexpression
induces an inflammatory gene
expression profile. (a) Gene
expression changes in
gastrocnemius muscle, illustrated
by a heatmap of the 25 most
highly induced genes in
Mcp-1-Tg mice compared with
WT mice. FC, fold change. (b)
Gene sets positively enriched in
the gastrocnemius of Mcp-1-Tg
mice ranked according to
normalised enrichment score
(GSEA). The enrichment score
reflects the degree towhich a gene
set is over-represented at the top
or bottom of a ranked list of
genes. Normalisation accounts for
differences in gene set size and in
correlations between gene sets
and the expression dataset
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electrotransfer had no effect on glucose disposal in muscle un-
der hyperinsulinaemic–euglycaemic clamp conditions, sug-
gesting that activation of the IκBKβ–NF-κB pathway in mus-
cle does not seem to be an important local mediator of insulin
resistance [31].
Presently, it is difficult to merge the diverse findings into a
coherent and consistent picture describing the role and impact
of inflammatory signalling in muscle on local insulin resis-
tance. A provocative conclusion emerging from our study and
other ‘negative’ studies is that obesity-induced insulin resis-
tance in muscle, the primary organ accounting for insulin-
mediated glucose disposal, is not dependent on inflammatory
signalling in muscle itself; this in turn can be extrapolated to
suggest that development of insulin resistance in muscle dur-
ing obesity does not require inflammatory mediators that af-
fect skeletal muscle. In future studies, more attention should
be accorded to clarification of the role of inflammatory signal-
ling from adipose tissue to muscle in the development of in-
sulin resistance.
In contrast to our findings, Patsouris et al observed modest
whole-body and muscle insulin resistance and mildly elevated
plasma glucose levels inMck–Mcp-1-Tgmice [25]. One of the
potential reasons for the discrepancy between our data and
those of Patsouris is the composition of the background diet,
as our chow diet and HFD are different from the diets used by
Patsouris et al. Another important difference between our
study and the study by Patsouris and colleagues is that we
measured plasma metabolic variables (i.e. insulin, glucose,
triacylglycerol) in 6 h-fasted mice, whereas Patsouris assessed
the same variables in fed mice. Unfortunately, additional rel-
evant experimental details (number of mice used, sex of the
mice, time of euthanasia) are not mentioned in the Patsouris
paper, which would have allowed for a more detailed compar-
ison between the two studies [25].
In contrast to the present study in mice with muscle-
specific overexpression of MCP1, studies performed in mice
with adipose tissue-specific overexpression of MCP-1 or ex-
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Fig. 3 Nometabolic phenotype is observed inmice overexpressingMcp-
1 in skeletal muscle under normal chow diet. (a) Tissue weights of
musculus gastrocnemius (Gastroc.), musculus vastus, liver and WAT;
n=8 (WT mice) or n=11 (Mcp-1-Tg mice). (b, c) Blood glucose level
during insulin tolerance test (b) and glucose tolerance test (c); n=8
(WTandMcp-1-Tg mice). (d) Representative western blot showing phos-
phorylation levels of Akt in gastrocnemius of WT and Mcp-1-Tg mice
upon insulin injection. Bar graph shows quantification of p-Akt/Akt ratio
performed in four mice per treatment group and normalised to WT mice
without insulin. (e–i) Plasma concentration of NEFA (e), triacylglycerol
(f), cholesterol (g), glucose (h) and insulin (i); n=8 (WT mice) or n=11
(Mcp-1-Tg mice). White bars and squares, WT mice; black bars and
squares, Mcp-1-Tg mice. Data are means±SEM; *p<0.05 according to
Student’s t test for insulin-treated mice vs control-treated mice (d)
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adipose tissue-derived MCP-1 reduces glucose tolerance and
insulin sensitivity and blunts insulin-mediated signalling in
skeletal muscle [11, 12]. Also, in vitro treatment of human
skeletal muscle cells or the C2C12 muscle cell line with re-
combinant MCP-1 protein results in decreased Akt phosphor-
ylation upon insulin stimulation [10, 11]. This raises the ques-
tion why MCP-1 secreted from adipose tissue is able to alter
whole-body and muscle insulin sensitivity whereas MCP-1
secreted from the muscle is not, especially since the levels of
plasma MCP-1 were comparable in both transgenic mouse
models [11, 12]. One explanation may be that circulating
MCP-1 only plays a minor role in regulating whole-body in-
sulin sensitivity and that local MCP-1 concentrations predom-
inantly determine the metabolic outcome: raising MCP-1
levels in muscle only results in local inflammation, while in-
creasedMCP-1 expression in adipose tissue starts a cascade of
events including altered adipose-resident immune cell profiles
and altered output of adipokines and metabolites, ultimately
resulting in impaired whole-body insulin sensitivity. It should
be noted, however, that acute or chronic elevation of circulat-
ing MCP-1 by injection results in insulin resistance [32].
Accordingly, a possible alternative explanation is that circu-
lating MCP-1 is able to affect insulin sensitivity but that the
form secreted by adipose tissue is different from the form
secreted by muscle tissue. It is known that MCP-1 exists in
an unglycosylated (8–12 kDa) and in a glycosylated form (17–
30 kDa) [33–35] and it has been suggested that the glycosyl-
ated form can bind to cell membranes, increasing the local
MCP-1 expression, while unglycosylated MCP-1 is more eas-
ily diffusible and able to form a potent chemotactic gradient
[36]. The MCP-1 protein detected by western blotting in this
study has a molecular mass of approximately 18 kDa, which
suggests that the MCP-1 expressed in skeletal muscle is
glycosylated. Furthermore, in vitro treatment of muscle cells
with MCP-1 and acute or chronic elevation of MCP-1 by
injection in vivo, which both resulted in insulin resistance,
were all performed with unglycosylated recombinant MCP-1
protein produced in E. coli [10, 11, 32]. More research is
therefore needed to investigate the glycosylation status of
MCP-1 originating from different tissues. Moreover, it would
be interesting to determine whether MCP-1 glycosylation
status influences insulin signalling in insulin-sensitive tissues.
By acting as a myokine and as an inflammatory mediator,
MCP-1 displays characteristics similar to those of IL-6, the
most studied and discussed myokine (reviewed in [22]). It has
been suggested that IL-6 produced by skeletal muscle has a
stimulatory influence on insulin sensitivity in skeletal muscle,
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Fig. 4 Characterisation of
muscle-specific Mcp-1-Tg mice
fed an HFD. (a) Relative gene
expression ofMcp-1measured by
qPCR. (b) Blood concentration of
MCP-1. (c) H&E staining of
representative sections of




Relative gene expression of Il6,
Il1b, F4/80 and Cd68 measured
by qPCR. (e): Body weight
changes in the WT andMcp-1-Tg
mice. (f) Average food intake
from week 2 to week 8. (g) Tissue
weights of musculus
gastrocnemius (Gastroc.),
musculus vastus, liver and WAT.
White bars and squares, WT
mice; black bars and squares,
Mcp-1-Tg mice. Data are means±
SEM; n=11 (WT mice) or n=12
(Mcp-1-Tg mice); **p<0.01 and
***p<0.001 according to
Student’s t test for WT vs
Mcp-1-Tg mice
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levels in adipose tissue and liver [23, 37–39]. Accordingly, the
effect of both MCP-1 and IL-6 on insulin sensitivity seems to
be very tissue-specific and may also depend on whether they
are induced acutely or chronically [22]. Examining the paral-
lels between MCP-1 and IL-6 may help unravel the underly-
ing mechanism accounting for the tissue-specific actions of
these two dual-faced regulators of glucose homeostasis.
A limitation of our study is that we only assessed muscle-
specific insulin signalling at the level of Akt phosphorylation
and did not examine other insulin-sensitive targets or perform
clamp studies. Another limitation is that we cannot rule out
that (obesity-induced) overexpression of MCP-1 specifically
during adulthood has a different effect on insulin action than
permanent MCP-1 overexpression in muscle starting during
embryonic development. Future studies using inducible
Mcp-1-Tg mice are necessary to clarify this issue.
In conclusion, elevation of MCP-1 production in skeletal
muscle and concomitant elevation of plasma MCP-1 lead to
enhanced inflammation in skeletal muscle but have no effect
on insulin resistance and glucose tolerance in lean and obese
mice and do not affect insulin-mediated signalling in skeletal
muscle.
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